Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Bassan R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: tanasi i. Leuk Res. 2022 Mar;114:106803. doi: 10.1016/j.leukres.2022.106803. Epub 2022 Feb 8. Leuk Res. 2022. PMID: 35150967 Free article.
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
Bonifacio M, Tiribelli M, Miggiano MC, Abruzzese E, Binotto G, Scaffidi L, Cordioli M, Damiani D, Di Bona E, Trawinska MM, Tanasi I, Dubbini MV, Velotta V, Ceccarelli G, Pierdomenico E, Lo Schirico M, Semenzato G, Ruggeri M, Fanin R, Tacconelli E, Pizzolo G, Krampera M. Bonifacio M, et al. Among authors: tanasi i. Cancer Med. 2021 Sep;10(18):6310-6316. doi: 10.1002/cam4.4179. Epub 2021 Aug 31. Cancer Med. 2021. PMID: 34464516 Free PMC article.
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Sancetta R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: tanasi i. Leuk Res. 2022 Apr;115:106811. doi: 10.1016/j.leukres.2022.106811. Epub 2022 Feb 24. Leuk Res. 2022. PMID: 35219543 No abstract available.
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, Giglio F, Salutari P, Audisio E, Scappini B, Zappasodi P, Defina M, Forghieri F, Scattolin AM, Todisco E, Lunghi M, Guolo F, Del Principe MI, Annunziata M, Lazzarotto D, Cedrone M, Pasciolla C, Imovilli A, Tanasi I, Trappolini S, Cerrano M, La Starza R, Krampera M, Di Renzo N, Candoni A, Pizzolo G, Ferrara F, Foà R. Dargenio M, et al. Among authors: tanasi i. Br J Haematol. 2023 Feb;200(4):440-450. doi: 10.1111/bjh.18537. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335916 Free PMC article.
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
Lazzarotto D, Tanasi I, Vitale A, Piccini M, Dargenio M, Giglio F, Forghieri F, Fracchiolla N, Cerrano M, Todisco E, Papayannidis C, Leoncin M, Defina M, Guolo F, Pasciolla C, Delia M, Chiusolo P, Mulè A, Candoni A, Bonifacio M, Pizzolo G, Foà R. Lazzarotto D, et al. Among authors: tanasi i. Ann Hematol. 2023 May;102(5):1099-1109. doi: 10.1007/s00277-023-05162-0. Epub 2023 Mar 24. Ann Hematol. 2023. PMID: 36959485
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (https://www.fisimematologia.it/). Lanino L, et al. Among authors: tanasi i. Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24. Am J Hematol. 2023. PMID: 37222267 Free article. No abstract available.
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia.
Takam Kamga P, Dal Collo G, Resci F, Bazzoni R, Mercuri A, Quaglia FM, Tanasi I, Delfino P, Visco C, Bonifacio M, Krampera M. Takam Kamga P, et al. Among authors: tanasi i. Cancers (Basel). 2019 Dec 6;11(12):1958. doi: 10.3390/cancers11121958. Cancers (Basel). 2019. PMID: 31817634 Free PMC article.
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del Principe MI, Giglio F, Defina M, Favre C, Rizzari C, Castella B, Pizzolo G, Ferrara F, Chiaretti S, Foà R. Cerrano M, et al. Among authors: tanasi i. Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851. Haematologica. 2022. PMID: 35021604 Free PMC article. No abstract available.
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
Coltro G, Sant'Antonio E, Palumbo GA, Mannelli F, De Stefano V, Ruggeri M, Elli EM, Zanotti R, Borsani O, Bertozzi I, Duminuco A, Betti S, Carli G, Cavalca F, Tanasi I, Rumi E, Randi ML, Garibaldi B, Loscocco GG, Guglielmelli P, Vannucchi AM. Coltro G, et al. Among authors: tanasi i. Cancer Med. 2023 Apr;12(7):8166-8171. doi: 10.1002/cam4.5618. Epub 2023 Jan 27. Cancer Med. 2023. PMID: 36708083 Free PMC article.
28 results